DiabSense is proud to be exhibiting at Latitude59 2025 in Tallinn, Estonia — showcasing our innovative solutions for early diabetic foot ulcer detection at the Startup Demo Area among global tech leaders.
🔗 View Event on LinkedIn
At DiabSense, we are dedicated to preventing diabetic foot complications before they begin. Our smart, AI-powered ecosystem enables early detection and continuous monitoring—helping reduce amputations, hospital visits, and long-term health costs.
We bridge the gap between home-based care and clinical diagnostics through innovative technology, making advanced foot health monitoring accessible, proactive, and reliable.
With a strong foundation in clinical expertise, medical device engineering, and global research partnerships, DiabSense is transforming diabetic care—one step at a time.
We introduce DiabSense, an AI-assisted, connected foot scanning solution with both clinical and at-home applications for proactive diabetic care.
45 million diabetic patients develop foot ulcers yearly. Our purpose is to bring down this number drastically by detecting infections before they spread.
Early Detect. Early Treat. Prevent Forever.
Innovating diabetic care through early detection and global collaboration
DiabSense is a specialized healthcare spin-off powered by our sister company, ExcelTech OÜ — a medical technology firm registered in Estonia and currently expanding its presence across Europe.
Focused on diabetic foot care, DiabSense delivers an advanced, dual-solution system — SoleSense+ for home use and FootScan Pro for clinical settings — to enable early detection and proactive prevention of diabetic foot ulcers.
Powerful innovation meets simplicity in diabetic foot monitoring.
Combines thermal and visual foot imaging for deeper insights.
Scans work seamlessly across home and clinical environments.
Enables early detection and reduces risk of limb loss.
User-friendly design that's budget-friendly and portable.
Supported by real trials and trusted by medical professionals.
Advanced technology for real-time remote insights and alerts.
Unique innovation protected by pending patents.
We’re addressing a growing crisis with a proven solution.
$45 Billion
$4 Billion
$800 Million
in deep-diabetic stages
face amputations annually
develop ulcers
